Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) has announced the full market release of its innovative Masimo W1™ health watch, which offers continuous monitoring of vital signs such as oxygen saturation, pulse rate, and hydration index. Designed for consumer use, the watch utilizes advanced technology known for its accuracy in challenging conditions. Additionally, it pairs with the Masimo Health™ app for insightful health data tracking. The launch includes the Personal SafetyNet™ subscription service for enhanced health monitoring over time.

Masimo (Nasdaq: MASI) reported strong Q2 2022 results with consolidated revenue of $565 million, an increase of 85.3% from $305.1 million in Q2 2021. Healthcare revenue grew by 17% to $357 million, while non-healthcare revenue reached $208 million. GAAP net income was $18.1 million ($0.33 per diluted share), with non-GAAP net income of $74.8 million ($1.35 per diluted share). The company repurchased 3 million shares for $401 million and provided optimistic guidance for Q3 and FY 2022.

Masimo (NASDAQ: MASI) will release its second quarter 2022 financial results after market close on August 9, 2022. The results will be reviewed in a conference call at 1:30 p.m. PT (4:30 p.m. ET) hosted by CEO Joe Kiani and CFO Micah Young. Masimo is recognized for its innovative medical monitoring technologies, including the SET pulse oximetry system, which has shown superior performance in numerous studies. The company's advancements aim to enhance patient outcomes while minimizing healthcare costs.

Masimo (NASDAQ: MASI) announced findings from a randomized trial published in the Journal of Clinical Anesthesia, showing that EEG-guided anesthesia using Masimo's SedLine technology reduces sevoflurane dosage in young children undergoing minor surgery. The trial involved 195 children, revealing a significant decrease in average sevoflurane concentrations during induction (4.80% vs. 5.67%) and maintenance (2.23% vs. 2.38%) phases. Additionally, burst suppression incidents were lower in the EEG group (3.1% vs. 10.9%). These results suggest potential for enhanced anesthesia management in pediatric populations.

Masimo (NASDAQ: MASI) released findings from a retrospective study in Telemedicine and e-Health analyzing the efficacy of its SafetyNet remote patient monitoring system for COVID-19 patients. Conducted by the University of Colorado, the study suggested that Masimo SafetyNet is associated with a decrease in hospital length of stay (LOS) without increasing readmission rates. Out of 1979 patients analyzed, those discharged with SafetyNet had a notable reduction in LOS of 36% when not on home oxygen. The research highlights the potential of home telemonitoring to ease hospital capacity issues during surges in COVID-19 cases.

Masimo (NASDAQ: MASI) announced findings from a study published in the American Journal of Emergency Medicine, indicating that its PVi® technology is effective for assessing the severity of obstructive respiratory disease in pediatric emergency patients. The study involved 133 patients, revealing that PVi values differ significantly based on disease severity and hospitalization needs. With 100% sensitivity and 85% specificity, PVi can aid clinicians in rapid triage decisions, reducing subjectivity in critical situations. This noninvasive tool could enhance treatment outcomes for children with respiratory ailments.

Masimo (NASDAQ: MASI) reported first-quarter 2022 results with revenue of $304.2 million, marking a 1.7% increase year-over-year. GAAP net income was $46.6 million or $0.81 per diluted share, down from $53.4 million or $0.92 a year earlier. Non-GAAP net income rose to $53.2 million or $0.93 per diluted share. The company also faced unexpected supply chain challenges but remains optimistic about achieving its growth targets in the healthcare sector. Non-GAAP revenue guidance for 2022 is set between $2,000 and $2,060 million.

Masimo (NASDAQ: MASI) celebrates its 33rd anniversary with the limited market launch of the W1™ health watch, marking a significant entry into consumer health technology. The W1 offers continuous monitoring of vital signs such as oxygen saturation (SpO₂), pulse rate, and respiration, leveraging Masimo's expertise in noninvasive monitoring. This initiative aims to improve personal health management and supports remote monitoring for chronic patients. A select group of early adopters can purchase the W1 at a 50% discount, contributing feedback for refinement.

Masimo (NASDAQ: MASI) announced results from a study published in the Journal of Cardiothoracic and Vascular Anesthesia showing that using SedLine Brain Function Monitoring during cardiac surgeries significantly reduces the need for vasoactive and inotropic drugs. The study involved 300 patients from the Montreal Heart Institute. Key findings included a 57% reduction in higher vasoactive and inotropic scores, shorter mechanical ventilation duration, less intraoperative bleeding, and lower fluid requirements. However, pEEG-guided anesthesia did not improve CPB separation outcomes. Further prospective studies are recommended.